31 October 2011 - Biotica nominates drug candidate, BC556, a cyclophilin inhibitor to treat Hepatitis C
Cyclophilin inhibition provides a high barrier to viral resistance in combination therapy.
24 October 2011 - Biotica announces the Sangamides
Biotica announces the Sangamides: a new class of compounds with potential to provide a key component of combination therapy in Hepatitis C.
14 September 2011 - Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan
The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging. Building on observations that rapamycin extends healthy lifespan in various species (Kaeberlein & Kennedy; Nature 2009), the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.
03 August 2011 - Biotica regains worldwide rights to its rapamycin analogue program
Biotica Technology Ltd. (Cambridge, UK) today announced that it has regained full rights from Pfizer Inc. (NYSE: PFE) to its rapamycin analogue program, including transfer of data and materials. Biotica’s rapamycin analogue program, partnered in 2006 with Wyeth Pharmaceuticals (acquired by Pfizer in October 2009), includes clinical candidates for the treatment of neuro-inflammatory and other diseases.
09 March 2011 - Biotica to present at the EASL International Liver Congress 2011 in Berlin
Biotica to present at the EASL International Liver Congress 2011 in Berlin
Cyclophilin inhibition provides a high barrier to viral resistance in combination therapy.
24 October 2011 - Biotica announces the Sangamides
Biotica announces the Sangamides: a new class of compounds with potential to provide a key component of combination therapy in Hepatitis C.
14 September 2011 - Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan
The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging. Building on observations that rapamycin extends healthy lifespan in various species (Kaeberlein & Kennedy; Nature 2009), the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.
03 August 2011 - Biotica regains worldwide rights to its rapamycin analogue program
Biotica Technology Ltd. (Cambridge, UK) today announced that it has regained full rights from Pfizer Inc. (NYSE: PFE) to its rapamycin analogue program, including transfer of data and materials. Biotica’s rapamycin analogue program, partnered in 2006 with Wyeth Pharmaceuticals (acquired by Pfizer in October 2009), includes clinical candidates for the treatment of neuro-inflammatory and other diseases.
09 March 2011 - Biotica to present at the EASL International Liver Congress 2011 in Berlin
Biotica to present at the EASL International Liver Congress 2011 in Berlin